Dr. Atkinson on Novel Combinations in Melanoma

Victoria Atkinson, MD
Published: Wednesday, Nov 29, 2017



Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

According to Atkinson, there are many novel ideas and combinations including talimogene laherparepvec (T-VEC; Imlygic) and injecting plasmas.

Additionally, the combination of LAG3 and PD-1 will have phase III results released early next year, explains Atkinson. Other combinations include IDO inhibitors with PD-1, which has potential to improve response and reduce toxicity.
 
SELECTED
LANGUAGE


Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

According to Atkinson, there are many novel ideas and combinations including talimogene laherparepvec (T-VEC; Imlygic) and injecting plasmas.

Additionally, the combination of LAG3 and PD-1 will have phase III results released early next year, explains Atkinson. Other combinations include IDO inhibitors with PD-1, which has potential to improve response and reduce toxicity.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x